Serum ferritin predicts mortality regardless of inflammatory and nutritional status in patients starting dialysis: A prospective cohort study

Blood Purification

Volumn 40, Issue 3, 2015, Pages 209-217

  Park, Kyoung Sook ^a   Ryu, Geun Woo ^a   Jhee, Jong Hyun ^a   Kim, Hyung Woo ^a   Park, Seohyun ^a   Lee, Sul A ^a   Kwon, Young Eun ^a   Kim, Yung Ly ^a   Ryu, Han Jak ^a   Lee, Mi Jung ^a   Han, Seung Hyeok ^a   Yoo, Tae Hyun ^a   Kim, Yong Lim ^b   Kim, Yon Su ^c   Yang, Chul Woo ^d   Kim, Nam Ho ^e   Kang, Shin Wook ^a   Park, Jung Tak ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d The Catholic University of Korea College of Medicine   (South Korea)

^e Chonnam National University Medical School   (South Korea)

Author keywords

Clinical outcome; End stage renal disease; Ferritin; Hemodialysis

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRITIN; IRON; SERUM ALBUMIN; UREA; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COHORT ANALYSIS; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON THERAPY; KOREA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; UREA NITROGEN BLOOD LEVEL; BACTERIAL INFECTIONS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY;

AGED; BACTERIAL INFECTIONS; BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; FERRITINS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS;

EID: 84940761625     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000438819     Document Type: Article

References (31)

1. Lipschitz DA, Cook JD, Finch CA A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med. 1974; 290: 1213-1216.
2. Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, Dominguez-Cabrera C, Hortal-Cascon L, Perez-Borges P, Vega-Diaz N, Saavedra-Santana P, Palop-Cubillo L. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis. 1999; 34: 508-513.
3. Kalantar-Zadeh K, Luft FC, Humphreys MH. Moderately high serum ferritin concentration is not a sign of iron overload in dialysis patients. Kidney Int. 1999; 56: 758-759.
4. Maiwall R, Kumar S, Chaudhary AK, Maras J, Wani Z, Kumar C, Rastogi A, Bihari C, Vashisht C, Sarin SK. Serum ferritin predicts early mortality in patients with decompensated cirrhosis. J Hepatol. 2014; 61: 43-50.
5. Rosario C, Zandman-Goddard G, Meyron-Holtz EG, DCruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Stills disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013; 11: 185.
6. Hazard JT, Drysdale JW. Ferritinaemia in cancer. Nature. 1977; 265: 755-756.
7. Kirkali Z, Guzelsoy M, Mungan MU, Kirkali G, Yorukoglu K. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor size and volume. Urol Int. 1999; 62: 21-25.
8. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2001; 37: 564-572.
9. Jenq CC, Hsu CW, Huang WH, Chen KH, Lin JL, Lin-Tan DT. Serum ferritin levels predict all-cause and infection-cause 1-year mortality in diabetic patients on maintenance hemodialysis. Am J Med Sci. 2009; 337: 188-194.
10. Hasuike Y, Nonoguchi H, Tokuyama M, Ohue M, Nagai T, Yahiro M, Nanami M, Otaki Y, Nakanishi T. Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol. 2010; 14: 349-355.
11. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2001; 38: 1251-1263.
12. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003; 42: 864-881.
13. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004; 19: 141-149.
14. Costa E, Pereira BJ, Rocha-Pereira P, Rocha S, Reis F, Castro E, Teixeira F, Miranda V, do Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Role of prohepcidin. inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol. 2008; 28: 677-683.
15. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl 2008; 111: S75-S81.
16. Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, Kovesdy CP, Kalantar-Zadeh K. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-Term hemodialysis patients. Nephrol Dial Transplant. 2013; 28: 1936-1945.
17. Hatamizadeh P, Ravel V, Lukowsky LR, Molnar MZ, Moradi H, Harley K, Pahl M, Kovesdy CP, Kalantar-Zadeh K. Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant. 2013; 28: 2889-2898.
18. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005; 16: 3070-3080.
19. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006; 1(suppl 1): S9-S18.
20. KDOQI; National Kidney Foundation: II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006; 47(5 suppl 3): S16-S85.
21. Fishbane S. Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial. 2008; 21: 217-220.
22. Crepaldi C, Brendolan A, Bordoni V, Carta MR, DIntini V, Gastaldon F. inguaggiato P, Ronco C. Iron management in hemodialysis patients: optimizing outcomes in Vicenza, Italy. Hemodial Int. 2003; 7: 216-221.
23. Akizawa T, Pisoni RL, Akiba T, Saito A, Fukuhara S, Asano Y, Hasegawa T, Port FK, Kurokawa K. Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dial Transplant. 2008; 23: 3643-3653.
24. Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A. inoue T, Itakura I, Nakanishi T. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014; 86: 845-854.
25. Levi S, Cozzi A, Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract Res Clin Haematol. 2005; 18: 265-276.
26. Kalousova M, Krechler T, Jachymova M, Kubena AA, Zak A, Zima T. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol. 2012; 33: 1695-1700.
27. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, Politi P, Durazzi SMT, Muretto P, Albertini F. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990; 322: 417-421.
28. Senol E, Ersoy A, Erdinc S, Sarandol E, Yurtkuran M. Oxidative stress and ferritin levels in haemodialysis patients. Nephrol Dial Transplant. 2008; 23: 665-672.
29. Nishio A, Chhatkuli BP, Ma JZ, Kalantari K. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients. Blood Purif. 2013; 36: 29-36.
30. Harada T, Baba M, Torii I, Morikawa S. Ferritin selectively suppresses delayed-Type hypersensitivity responses at induction or effector phase. Cell Immunol. 1987; 109: 75-88.
31. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003; 14: 3270-3277.